Table 1.
Baseline demographic and clinical characteristics
| Fasiglifam | ||||
|---|---|---|---|---|
| Placebo | 25 mg | 50 mg | Total | |
| No. of participants | 67 | 63 | 62 | 192 |
| Age (years) | 61.1 (9.2) | 60.2 (10.5) | 59.8 (10.9) | 60.4 (10.1) |
| Male | 46 (68.7) | 43 (68.3) | 47 (75.8) | 136 (70.8) |
| Female | 21 (31.3) | 20 (31.7) | 15 (24.2) | 56 (29.2) |
| BMI (kg/m2) | 24.85 (3.70) | 24.79 (3.90) | 25.27 (3.60) | 24.97 (3.72) |
| Duration of diabetes (years) | 6.66 (6.50) | 5.01 (4.41) | 5.00 (4.43) | 5.58 (5.27) |
| HbA1c (%) | 7.83 (0.917) | 7.84 (0.847) | 7.69 (0.728) | 7.79 (0.835) |
| FPG (mmol/l) | 8.69 (1.69) | 8.66 (1.73) | 8.54 (1.78) | 8.63 (1.73) |
| Fasting insulin (μIU/ml) | 6.96 (3.837) | 7.28 (7.807) | 7.21 (4.669) | 7.15 (5.644) |
Data are mean (s.d.) or number of participants (%). BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin.